A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II

Generium

Status and phase: Enrolling; Phase 3; Phase 2

Conditions: Metabolic Diseases; Mucopolysaccharidosis Type II

Treatments: Drug: GNR-055 3.0 mg/kg; Drug: GNR-055 2.0 mg/kg; Drug: GNR-055 1.0-2.0-3.0 mg/kg

Study type: Interventional

Funder types: Industry

Identifiers

NCT05208281

IDB-MPS-II-III

Details and patient eligibility

About

This is phase 2/3 study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational product GNR-055 in MPS II (Hunter syndrome) patients of different age groups.

Full description

GNR-055 is intended for ERT in patient with Mucopolysaccharidosis type II (MPS II), or Hunter syndrome. MPS II is a recessive X-linked inheritance lysosomal storage disease, which is characterized by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (ID2S), caused by a mutation in the ID2S gene. Enzyme deficiency leads to the accumulation of Glycosaminoglycans (GAG) (mainly of heparan and dermatan sulfates) in lysosomes of almost all types of cells of various tissues and organs. The disease is manifested by growth retardation, damage of many organs and systems, severe deformations of bones and joints, gross facial features, pathology of the respiratory and cardiovascular systems, damage to parenchymal organs (hepatosplenomegaly), and hearing impairment. A severe form of the disease occurs with the involvement of the nervous system in the pathological process, including mental retardation, behavior anomalies, and impaired motor function.

GNR-055 is a recombinant modified ID2S capable to penetrate the blood-brain barrier and thus expected to prevent neurodegenerative consequences and the cognitive deficit and to attain a significant improvement in the life quality and expectancy of patients with MPS II.

Study IDB-MPS-II-III is a multicenter, open-label, multi-cohort study to assess safety, PK and PD, and efficacy of GNR-055 in patients of different age groups with MPS II (Hunter syndrome).

Enrollment: 32 estimated patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed inform consent;
• Verified diagnosis of MPS II (Hunter syndrome);
• Naïve patients or patients who have received standard ERT whit idursulfase products;
• No contraindications for lumbar puncture as judged by the Investigator;
• Willingness and ability to follow study procedures.

Exclusion criteria

• Clinically pronounced hypersensitivity to ID2S or any other component of the drug product;
• History of hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation;
• Implanted or external non-removable metal devices, a cardiac pacemaker, or other objects sensitive to the magnetic field that may pose a danger to both the wearer and the correct operation of magnetic resonance imaging (MRI) equipment;
• Concomitant diseases and conditions that, in the Investigator's opinion, can put at risk the patient's safety during his/her participation in the study, or which will influence the safety data analysis in case of the disease/condition exacerbation during the study.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

32 participants in 3 patient groups

Adult: GNR-055

Experimental group

Description:

GNR-055: 1.0-2.0-3.0 mg/kg

Treatment:

Drug: GNR-055 1.0-2.0-3.0 mg/kg

Paediatric: GNR-055 2.0 mg/kg

Experimental group

Description:

GNR-055 2.0 mg/kg

Treatment:

Drug: GNR-055 2.0 mg/kg

Paediatric: GNR-055 3.0 mg/kg

Experimental group

Description:

GNR-055 3.0 mg/kg

Treatment:

Drug: GNR-055 3.0 mg/kg